Oral Direct-Acting Agent Therapy for Hepatitis C Virus Infection: A Systematic Review
Jodi B Segal, David R. Nelson, Oluwaseun Falade‐Nwulia, Mark Sulkowski, Michael Fried, Catalina Suarez‐Cuervo
Abstract
Rapid improvements in hepatitis C virus (HCV) therapy have led to the approval of multiple oral direct-acting antiviral (DAA) regimens by the U.S. Food and Drug Administration (FDA) for treatment of chronic HCV infection.
Topics & Concepts
VirologyMedicineHepatitis C virusVirusHepatitis C virus research